Karpin (Amlodipine)

Amlodipine blocks L‑type calcium channels in vascular smooth muscle and cardiac cells, decreasing calcium entry. This causes arterial vasodilation, lowers peripheral resistance, and reduces myocardial oxygen demand, resulting in blood‑pressure reduction and angina relief.

The dose of Karpin is individualized by the prescribing clinician based on the patient’s blood‑pressure goals, clinical response, and tolerability. The prescriber determines the appropriate starting and maintenance doses.

Safety of amlodipine in pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To order Karpin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with other calcium‑channel blockers, amlodipine has a long half‑life and provides once‑daily dosing with a lower incidence of reflex tachycardia. It is often chosen for its predictable blood‑pressure‑lowering effect and favorable tolerability profile relative to some beta‑blockers or ACE inhibitors.

Karpin should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain potency throughout the shelf life.

Karpin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed.

Serious risks include severe hypotension, myocardial infarction, hepatic dysfunction, life‑threatening arrhythmias, Stevens‑Johnson syndrome, and angioedema. Patients should seek immediate medical attention if they experience symptoms such as fainting, chest pain, jaundice, rash, or swelling of the face or throat.

Karpin is contraindicated in patients with known hypersensitivity to amlodipine or any excipients, as well as those with severe aortic stenosis, cardiogenic shock, or unstable heart failure. Clinicians should evaluate each patient’s medical history before prescribing.